To determine tumor-related factors that influence the response of metastatic melanoma tumors to treatment with the anti-CTLA-4 antibody ipilimumab, researchers have performed gene-profiling assays on biopsies collected from 45 patients before and after treatment with ipilimumab. In patients who responded to treatment, expression of immune-related genes increased, and expression of genes associated with cell proliferation and melanoma-specific antigens decreased. These data indicate that cell-mediated immune responses have a role in the activity of ipilimumab.
ORIGINAL RESEARCH PAPER
Ji, R. R. et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. doi:10.1007/s00262-011-1172-6
Rights and permissions
About this article
Cite this article
Gene profiling hints at ipilimumab mechanism of action. Nat Rev Clin Oncol 9, 66 (2012). https://doi.org/10.1038/nrclinonc.2011.206
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.206